Promises and challenges of a decentralized CAR T-cell manufacturing model

Overview
This review makes the case for manufacturing autologous CAR T cells inside the hospital rather than at a central plant. It puts the cost at as little as 35,000 USD per patient when a sponsor supplies the vector, against nearly 500,000 USD for a commercial product, and turnaround at 7-10 days instead of 14.
What this paper found
Point-of-care manufacturing of autologous CAR T cells within academic healthcare systems is presented as a way to widen patient access and cut costs relative to the centralized commercial model, provided quality can be standardized. Commercial products total nearly $500,000 and patients may wait up to 3 weeks for a manufacturing slot. Decentralized production can shorten manufacturing to 7-10 days instead of 14 and may cost as little as $35,000 when a sponsor supplies the vector. Closed automated platforms such as CliniMACS Prodigy and Cocoon support this model. Main hurdles are GMP vector supply, trained staff, quality control, facilities and financing.
Note: This is a narrative review; the authors note that there are no commercially available point-of-care CAR T products in the USA and that comparability across sites must still be shown.
Quality control is one of the greatest challenges to implementing POC manufacturing as opposed to centralized manufacturing. — Manan Shah, Ashley Krull, Lynn Odonnell, Marcos J. de Lima, Evandro Bezerra, Frontiers in Transplantation
Study details
- Authors
- Manan Shah, Ashley Krull, Lynn Odonnell, Marcos J. de Lima, Evandro Bezerra
- Institution
- Department of Hematology, the James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH, United States · Department of Cell Therapy Manufacturing and Engineering, the James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH, United States · Department of Hematology, Cellular Therapy Lab, the James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH, United States
- Journal
- Frontiers in Transplantation
- Year
- 2023
- Cell type(s)
- CAR T Cells
- Application area
- Hematologic malignancy
Explore related
Full citation
Shah M, Krull A, Odonnell L, de Lima MJ, Bezerra E. Promises and challenges of a decentralized CAR T-cell manufacturing model. Front Transplant. 2023;2:1238535.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.